Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma

被引：3

作者：

Kim, Yuna ^{[1
]}

Lee, Han Ah ^{[2
]}

Lee, Jae Seung ^{[1
]}

Jeon, Mi Young ^{[1
]}

Kim, Beom Kyung ^{[1
,3
,4
]}

Park, Jun Yong ^{[1
,3
,4
]}

Kim, Do Young ^{[1
,3
,4
]}

Ahn, Sang Hoon ^{[1
,3
,4
]}

Um, Soon Ho ^{[2
]}

Seo, Yeon Seok ^{[2
]}

Kim, Seung Up ^{[1
,3
,4
]}

机构：

[1] Yonsei Univ, Coll Med, Dept Internal Med, Yonsei Ro 50, Seoul, South Korea

[2] Korea Univ, Coll Med, Dept Internal Med, 126-1 Anam Dong,5 Ga, Seoul, South Korea

[3] Yonsei Univ, Coll Med, Inst Gastroenterol, Seoul, South Korea

[4] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea

来源：

CANCER INVESTIGATION | 2021年 / 39卷 / 03期

基金：

新加坡国家研究基金会;

关键词：

TARE; radioembolization; Yttrium-90; hepatocellular carcinoma; curative treatment;

D O I：

10.1080/07357907.2020.1870126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Transarterial radioembolization (TARE) is one of the therapeutic options for hepatocellular carcinoma (HCC). This study aimed to investigate the predictors and prognostic values of achieving curative treatments after TARE. Overall, 143 patients with intrahepatic HCC treated with TARE between 2011 and 2017 were recruited from two Korean tertiary institutes. Twenty-seven patients received curative treatments after TARE. Younger age than 65 years and AFP of <= 200 ng/mL independently predicted the increased probability of achieving curative treatment after TARE, and the curative treatment after TARE provided a survival benefit in patients with intrahepatic HCC.

引用

页码：274 / 283

页数：10

共 38 条

[1]

[Anonymous], 2019, GUT LIVER, V13

[2] Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma [J].

Aravinthan, Aloysious D. ;

Bruni, Silvio G. ;

Doyle, Adam C. ;

Thein, Hla-Hla ;

Goldaracena, Nicolas ;

Issachar, Assaf ;

Lilly, Leslie B. ;

Selzner, Nazia ;

Bhat, Mamatha ;

Sreeharsha, Boraiah ;

Selzner, Markus ;

Ghanekar, Anand ;

Cattral, Mark S. ;

McGilvray, Ian D. ;

Greig, Paul D. ;

Renner, Eberhard L. ;

Grant, David R. ;

Sapisochin, Gonzalo .

ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (07) :1843-1851

[3]

CHAPMAN W, 2008, ANN SURG, V248

[4]

CHONG CN, 2012, SURGEON, V10

[5]

ETTORRE G, 2017, WORLD J SURG, V41

[6] Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis [J].

Facciorusso, Antonio ;

Serviddio, Gaetano ;

Muscatiello, Nicola .

WORLD JOURNAL OF HEPATOLOGY, 2016, 8 (18) :770-778

[7]

FARINATI F, 2006, AM J GASTROENTEROLOG, V101

[8] Hepatocellular carcinoma [J].

Forner, Alejandro ;

Reig, Maria ;

Bruix, Jordi .

LANCET, 2018, 391 (10127) :1301-1314

[9] Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model [J].

Fox, R. ;

Berhane, S. ;

Teng, M. ;

Cox, T. ;

Tada, T. ;

Toyoda, H. ;

Kumada, T. ;

Kagebayashi, C. ;

Satomura, S. ;

Johnson, P. J. .

BRITISH JOURNAL OF CANCER, 2014, 110 (08) :2090-2098

[10]

Golfieri R, 2014, HEPAT ONCOL, V1, P265, DOI [10.2217/HEP.14.6, 10.2217/hep.14.6]

← 1 2 3 4 →